R&D The role of the opioid pathway in schizophrenia and bipolar ... Psychiatry has spent decades focused on dopamine, serotonin, norepinephrine, and glutamate.
R&D Sponsored Advancing RSV and hMPV research through human challenge tria... Human challenge trials offer a complementary approach, and hVIVO has been at the forefront of this field for decades.
R&D Sponsored Best practices in cardiometabolic trial design: Planning and... Cardiometabolic disease is not a single entity. It is a broad spectrum of disorders that share common drivers.
R&D Whole-genome sequencing in the UK and Europe, with Mark Robi... Whole-genome sequencing provides an unbiased and complete view of the human genome and enables the discovery of genetic variation.
R&D AMR and vaccines: Can universal coverage avert a post-antibi... Antimicrobial resistance (AMR) is a growing global health crisis.
R&D Treating the chronic diseases GLP-1s miss, with Laurent Auda... Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
